Greenland Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Greenland Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Buy	+100,000	New	+$974K	0.16%	114

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Greenland Capital Management's FDMT Position: Q2 2026 in Review

Greenland Capital Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 72,257 shares worth $961K. The stake represents 0.12% of the portfolio and ranks #144 among its holdings.

158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Greenland Capital Management held 72,257 shares of 4D Molecular Therapeutics worth $961K as of Q2 2026.
4D Molecular Therapeutics was a new Greenland Capital Management position in Q2 2026.
4D Molecular Therapeutics made up 0.12% of Greenland Capital Management's portfolio in Q2 2026, its #144 holding.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Greenland Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.